BioXcel Therapeutics (BTAI) PT Lowered to $13 at Goldman Sachs
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $0.07 --0%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 13 | New: 48
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 13 | New: 48
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $13.00 (from $25.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Okta, Inc (OKTA) PT Raised to $235 at DA Davidson Following Oktane 2026
- Paychex (PAYX) PT Lowered to $115 at UBS on Pace of Revenue Growth
- Cintas (CTAS) PT Raised to $235 at UBS Following Beat-and-Raise Quarter
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
